AstraZeneca PLC (AZN)vsScinai Immunotherapeutics Ltd (SCNI)
AZN
AstraZeneca PLC
$185.95
-0.79%
HEALTHCARE · Cap: $282.69B
SCNI
Scinai Immunotherapeutics Ltd
$0.41
-6.08%
HEALTHCARE · Cap: $1.47M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 4610045% more annual revenue ($60.44B vs $1.31M). AZN leads profitability with a 17.2% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
SCNI
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Intrinsic value data unavailable for SCNI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Reasonable price relative to book value
Revenue surging 30.6% year-over-year
Earnings expanding 87.2% YoY
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
ROE of -102.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : SCNI
The strongest argument for SCNI centers on Price/Book, Revenue Growth, EPS Growth. Revenue growth of 30.6% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : SCNI
The primary concerns for SCNI are Market Cap, Profit Margin, Piotroski F-Score.
Key Dynamics to Monitor
AZN profiles as a mature stock while SCNI is a hypergrowth play — different risk/reward profiles.
SCNI carries more volatility with a beta of 2.05 — expect wider price swings.
SCNI is growing revenue faster at 30.6% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 51/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Scinai Immunotherapeutics Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Scinai Immunotherapeutics Ltd is a cutting-edge biotechnology company specializing in the development of innovative immunotherapy solutions aimed at treating cancer and autoimmune disorders. Utilizing its proprietary immune modulation platform, Scinai is advancing a robust clinical pipeline that focuses on delivering transformative therapies to improve patient outcomes. With a highly experienced leadership team and a commitment to rigorous research, the company is well-positioned to capitalize on the growing demand for advanced immunotherapeutics in the global healthcare landscape. Strategic partnerships further enhance Scinai's potential for significant growth, establishing it as a key player in the biopharmaceutical sector.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?